NCT05668520

Brief Summary

It is known that weight loss is a poor prognostic marker in HD, but it is not known which dietary interventions are optimal at different stages of the disease. Current guidelines for HD treatment are informed only by studies in people with other causes of weight loss. Our long term goal is to create the evidence base for improved nutritional management in HD. This study will pilot the tools to inform the development of clinical trials protocols. We want to know which measures can be used by patients manifesting obvious clinical features of HD, and which are most helpful in detecting clinically meaningful changes in nutrition status.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Oct 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2022

Completed
1 day until next milestone

Study Start

First participant enrolled

October 1, 2022

Completed
3 months until next milestone

First Posted

Study publicly available on registry

December 29, 2022

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2023

Completed
Last Updated

December 29, 2022

Status Verified

December 1, 2022

Enrollment Period

1 year

First QC Date

September 30, 2022

Last Update Submit

December 20, 2022

Conditions

Outcome Measures

Primary Outcomes (6)

  • satisfactory completion of body composition

    measurement of body composition using hand-held body fat monitor

    assessed at study visit for each participant

  • measurement of resting metabolic rate

    measurement of Resting Metabolic Rate (RMR) using a ventilated hood system

    assessed at study visit for each participant

  • measurement of body weight

    body weight in kg

    assessed at study visit for each participant

  • measurement of height

    height in metres

    assessed at study visit for each participant

  • completion of measurement of waist, arm and calf circumference

    measurement of waist circumference, mid upper arm and calf circumference using a tape measure

    assessed at study visit for each participant

  • nutritional assessment

    estimation of energy, protein, carbohydrate and fat intake using MNA and MUST questionnaires

    assessed at study visit for each participant

Secondary Outcomes (1)

  • variability of measures to power future grant applications

    at end of study

Study Arms (2)

weight stable

stage 2 and 3 as defined by the UHDRS Total Functional Capacity score will be recruited. Ten will have reported at least 5% weight loss in a 12-month period,

Diagnostic Test: Body composition using a hand-held body fat monitor • Resting Metabolic Rate (RMR) using a ventilated hood system

weight loss

stage 2 and 3 as defined by the UHDRS Total Functional Capacity score will be recruited. Ten will have reported at least 5% weight loss in a 12-month period,

Diagnostic Test: Body composition using a hand-held body fat monitor • Resting Metabolic Rate (RMR) using a ventilated hood system

Interventions

Consent Paperwork * Nutritional assessment using MNA and MUST questionnaires * 24-hour dietary recall assessment Body weight, height, waist circumference, mid upper arm and calf circumference

Also known as: Nutritional assessment
weight lossweight stable

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

manifesting Huntington disease patients of North of Scotland Huntington's clinic

You may qualify if:

  • stage 2 or 3 Huntington disease

You may not qualify if:

  • unable to give consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Zosia Miedzybrodzka

Aberdeen, Scotland, AB25 2ZA, United Kingdom

Location

MeSH Terms

Conditions

Huntington Disease

Condition Hierarchy (Ancestors)

Basal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesDementiaChoreaDyskinesiasMovement DisordersHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesCognition DisordersNeurocognitive DisordersMental Disorders

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 30, 2022

First Posted

December 29, 2022

Study Start

October 1, 2022

Primary Completion

October 1, 2023

Study Completion

October 1, 2023

Last Updated

December 29, 2022

Record last verified: 2022-12

Locations